Home > Insider Trading > Filing (0001209191-18-012579)

Filing Details

Accession Number:: 0001209191-18-012579
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-02-22 18:04:59
Reporting Period:: 2018-02-21

Accepted Time:: 2018-02-22 18:04:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1446847	Ironwood Pharmaceuticals Inc	IRWD	Pharmaceutical Preparations (2834)	043404176

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1601360	E Halley Gilbert	C/O Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2018-02-21	2,343	$14.66	99,602	No	4	S	Direct
Class A Common Stock	Disposition	2018-02-21	2,411	$14.66	97,191	No	4	S	Direct
Class A Common Stock	Disposition	2018-02-21	2,987	$14.66	94,204	No	4	S	Direct
Class A Common Stock	Acquisiton	2018-02-21	35,000	$0.00	129,204	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Employee Stock Option(Right to Buy)	Acquisiton	2018-02-21	70,000	$0.00	70,000	$14.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,000		2028-02-21	No	4	A	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The reporting person acquired a total of 1,138 shares of Class A Common Stock under the issuer's employee stock purchase plan in the following transactions: 791 shares acquired on June 30, 2017 and 347 shares acquired on December 31, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018.